The safety of vandetanib for the treatment of thyroid cancer.

about

Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.Novel therapeutic clues in thyroid carcinomas: The role of targeting cancer stem cells.

P2860

Q38683133-5A3E21DC-FF73-4C0D-BA20-F238136AB239 Q39354316-1600631A-7EA6-43A5-89B7-38E023422928

P2860

The safety of vandetanib for the treatment of thyroid cancer.

Item

http://www.wikidata.org/entity/Q38864998

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

The safety of vandetanib for the treatment of thyroid cancer.

@en

type

Item

label

The safety of vandetanib for the treatment of thyroid cancer.

@en

prefLabel

The safety of vandetanib for the treatment of thyroid cancer.

@en

P1476

The safety of vandetanib for the treatment of thyroid cancer.

@en

P2093

Bruce G Robinson

http://www.w3.org/2001/XMLSchema#string

Diana L Learoyd

http://www.w3.org/2001/XMLSchema#string

Venessa H M Tsang

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer

Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.

Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.

RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors.

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.

P304

1107-1113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14740338.2016.1201060

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27301016

http://www.w3.org/2001/XMLSchema#string

The safety of vandetanib for the treatment of thyroid cancer.

about

P2860

P2860

The safety of vandetanib for the treatment of thyroid cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698